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Background: Chronic kidney disease (CKD) is a well-known risk factor for coronary artery dis-
ease and is associated with poor outcomes following an acute coronary syndrome (NSTE-ACS).
The optimal timing of an invasive strategy in patients with CKD and NSTE-ACS is unclear.
Hypothesis: Timing of PCI in CKD patients will not affect the risk of mortality or incidence of
dialysis.
Methods: We queried the National Inpatient Sample database (NIS) to identify cases with
NSTEMI and CKD. Patients who underwent percutaneous coronary intervention (PCI) day 0 or
1 vs day 2 or 3 after admission were categorized as early vs delayed PCI, respectively. The pri-
mary outcomes of the study were in-hospital mortality and acute kidney injury requiring hemo-
dialysis (AKI-D). The secondary outcomes were length of stay and hospital charges. Baseline
characteristics were balanced using propensity score matching (PSM).
Results: After PSM, 3708 cases from the delayed PCI group were matched with 3708 cases
from the early PCI group. The standardized mean differences between the 2 groups were sub-
stantially reduced after PSM. All other recorded variables were balanced between the 2 groups.
In the early and delayed PCI groups, the incidence of AKI-D (2.5% vs 2.3%; P = 0.54) and in-
hospital mortality (1.9% vs 1.4%; P = 0.12) was similar. Hospital charges and length of stay
were higher in the delayed PCI group.
Conclusions: The incidence of AKI-D and in-hospital mortality among patients with CKD and
NSTE-ACS were not significantly affected by the timing of PCI. However, delayed PCI added signifi-
cant cost and length of stay. A prospective randomized study is required to validate this concept.
KEYWORDS
Acute Coronary Syndrome, Cardiac Catheterization/Diagnostic, Interventional, Kidney Disease
1 | INTRODUCTION
The optimal timing of coronary angiography and revascularization for
patients with chronic kidney disease (CKD) presenting with an acute
non–ST-segment elevation acute coronary syndrome (NSTE-ACS) is
controversial. There are no studies examining the effect of an early
vs delayed strategy for these patients on short-term outcomes such
as in-hospital mortality and acute kidney injury requiring dialysis
(AKI-D). Although the current non–ST-segment elevation myocardial
infarction (NSTEMI) guidelines recommend an invasive strategy for
patients with CKD and no other serious comorbidity or
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contraindication to the procedure, there are no specific recommenda-
tions on optimal timing.1 The European guideline recommends an
early invasive strategy for the high-risk patient, wherein moderate to
severe renal dysfunction is considered an intermediate risk factor.2
Many studies have shown that an early invasive strategy, com-
pared with a delayed invasive treatment strategy, reduces the inci-
dence of cardiovascular death and myocardial infarction (MI),
whereas others have demonstrated no significant difference.3–10 The
concern with an immediate strategy is that early intervention on
unstable plaque can lead to coronary emboli and microvascular
obstruction. The concern with a delayed invasive approach is that it
places patients at risk for recurrent ischemia and infarction. Very
recently, a published meta-analysis concluded that an early invasive
strategy does not reduce the risk for death of MI compared with a
delayed strategy.11 However, none of the published studies examined
the effect of an early vs delayed strategy on outcomes in patients
with CKD. To assess the value of early vs delayed percutaneous coro-
nary intervention (PCI) in patients with CKD and NSTEMI, we ana-
lyzed a large national database, comparing the incidence of AKI-D
and in-hospital mortality.
2 | METHODS
We queried the National Inpatient Sample (NIS) from 2010 to 2014
to identify patients with CKD and NSTEMI. The NIS is part of the
Healthcare Cost and Utilization Project (HCUP) and represents
approximately 20% of all inpatient admissions from participating hos-
pitals.12 The publicly available database contains de-identified patient
information. It provides International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM) diagnoses, procedure codes,
demographic information, and patient discharge status. It also con-
tains Clinical Classification Software (CCS), which are clusters of simi-
lar diagnoses that can be used to identify diagnoses or procedures.
Conditions such as obesity, hypertension, peripheral vascular disease,
depression, fluid and electrolyte disorders, coagulopathy, chronic pul-
monary disease and diabetes mellitus (DM) are also included in the
database as Elixhauser comorbidities. Refer to Table 1 for the ICD-9-
CM and CCS diagnosis and procedure codes used in the study.
We identified a cohort of patients with CKD who underwent PCI
for NSTEMI. Patients with CKD were identified using ICD-9-CM
codes 585.1, 585.2, 585.3, 585.4, 585.5, and 585.9. We included
patients age ≥ 18 years with NSTE-ACS who underwent PCI with
bare-metal or drug-eluting stent(s). Patients with concomitant diagno-
sis of ST-segment elevation myocardial infarction (STEMI) were
excluded. We restricted our cohort to those undergoing PCI. Patients
undergoing PCI on day 0 or 1 after admission were categorized as
the early PCI group; patients undergoing PCI on day 2 or 3 after
admission were categorized as the delayed PCI group. Patients under-
going cardiac surgery during the same admission were excluded.
When a patient underwent PCI on 2 separate days, the first day of
stenting was considered the index day of the procedure. Patients
whose index procedure day of stenting was on or after the fourth
day of admission or patients who had staged PCI anytime after the
index PCI during the same hospitalization were also excluded from
the study. Elective admissions and cases with missing values for age,
race, mortality data, and timing of PCI were excluded (Table 2).
There is no single ICD-9-CM code for contrast-induced nephrop-
athy (CIN). To identify patients with CIN requiring dialysis, we used
ICD-9-CM codes for AKI plus ICD-9-CM codes for dialysis. We
excluded patients who only had the ICD-9-CM code for end-stage
TABLE 1 Diagnosis and procedure codes
Diagnosis or Procedure ICD-9-CM or CCS Codes
Inclusion criteria
NSTEMI 410.7, 410.70–410.72, 411.1
CKD 585.1–585.5, 585.9
BMS and DES 36.06, 36.07
Exclusion criteria
ESRD 585.6
Dialysis 39.95, 54.98
Valvular or CABG surgery Procedure CCS: 43 and 44
STEMI 410.×1 (410.01–410.91)
Comorbidities
Prior MI 412
Smoking V15.82, 305.1
Dyslipidemia CCS code: 53
Acute CVA CCS code: 109
Prior revascularization V45.81, V45.82
Chronic ASA use V58.66
AKI 584, 585.4–585.9
Family history of CAD V17.3
Cardiogenic shock 785.51
Ventricular arrhythmias 427.1, 427.4, 427.41, 427.42
Abbreviations: AKI, acute kidney injury; ASA, acetylsalicylic acid (aspirin);
BMS, bare-metal stents; CABG, coronary artery bypass grafting; CAD,
coronary artery disease; CCS, Clinical Classification Software; CKD,
chronic kidney disease; CVA, cerebrovascular accident; DES, drug-eluting
stents; ESRD, end-stage renal disease; ICD-9-CM, International Classifica-
tion of Diseases, Ninth Revision, Clinical Modification; MI, myocardial infarc-
tion; NSTEMI, non–ST-segment elevation myocardial infarction; STEMI,
ST-segment elevation myocardial infarction.
TABLE 2 Inclusion and exclusion criteria
Inclusion criteria
Age ≥ 18 y
CKD
PCI
NSTEMI
Exclusion criteria
Missing information for in-hospital mortality data and timing of PCI
Elective admissions
ESRD without mention of AKI
STEMI
Valvular surgery or CABG during the same admission
Pre-admission, index PCI on or after fourth day of admission
Repeat procedure (staged PCI) after index procedure
Abbreviations: AKI, acute kidney injury; CABG, coronary artery bypass
grafting; CKD, chronic kidney disease; ESRD, end-stage renal disease;
NSTEMI, non–ST-segment elevation myocardial infarction; PCI, percuta-
neous coronary intervention; STEMI, ST-segment elevation myocardial
infarction.
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renal disease or a procedure code for dialysis without the mention of
AKI. The primary outcomes of interest were in-hospital mortality and
AKI-D. The secondary outcomes were total charges and length
of stay.
2.1 | Statistical analysis
The statistical analyses was performed using SPSS software, version
24 (IBM Corp., Armonk, NY). For propensity score matching (PSM),
we used 1:1, logistic algorithm, nearest neighbor variable within cali-
per width of 0.01. Cases were matched for “Delayed” with “Early”
group. The following variables were entered in the PSM algorithm:
age, race, sex, weekend admission, prior history of MI, smoking, dysli-
pidemia, DM, acute cerebrovascular accident, prior history of revas-
cularization, chronic aspirin use, AKI, cardiogenic shock, chronic lung
disease, coagulopathy, depressive disorders, hypertension, obesity,
ventricular arrhythmias, fluid and electrolyte disorders, and peripheral
vascular disease. Because we analyzed ≥1 year of data, we included
years 2010 to 2014 into PSM to control for year-to-year variations.
We used unweighted, matched cases for further analysis and
reported both before and after PSM data. Categorical and continuous
variables were analyzed with the χ2 and Mann–Whitney U test. A 2-
sided P value of <0.05 was considered statistically significant. The
categorical variables were reported as percentages, and continuous
variables were reported as median with interquartile range.
3 | RESULTS
3.1 | Baseline characteristics and PSM analysis
The initial cohort prior to PSM included 7705 unweighted cases in
the early PCI group and 3946 cases in the delayed PCI group. After
PSM, 3708 cases were selected out of 3946 cases (94%) and were
matched with 3708 cases from the early PCI group (Table 3). The
median age of the patients for both groups was 73 years. A higher
proportion of patients admitted on weekends was more likely to have
delayed PCI (34.9% vs 17%; P < 0.001). Before PSM, Caucasians,
TABLE 3 Patient characteristics before and after PSM
Before PSM After PSM
Early PCI Delayed PCI P Value Early PCI Delayed PCI P Value
Variables n = 7705 n = 3946 n = 3708 n = 3708
Age, y, median (IQR) 73 (64–80) 73 (65–81) 0.003 74 (65–81) 73 (65–81) 0.26
Caucasian, % 70.7 72.5 <0.001 73.1 72.1 0.76
Weekend admission, % 17.0 34.9 <0.001 30.6 30.9 0.76
Female sex, % 35.5 37.1 0.1 37.7 36.9 0.49
Chronic pulmonary disease 22.4 25.1 0.001 24.8 24.8 0.98
Coagulopathy 4.9 5.3 0.26 5.4 5.3 0.84
Depression 8.7 8.8 0.79 8.9 9.0 0.87
HTN 88.6 88.2 0.52 87.9 88.3 0.64
Fluid and electrolyte disorders 20.9 28.6 <0.001 26.8 27.8 0.36
Acute CVA 0.8 0.9 0.65 1.0 0.9 0.81
Obesity 20.5 20.8 0.68 21.0 20.9 0.93
PVD 20.9 22.3 0.08 21.7 22.0 0.76
DM 57.0 59.9 0.003 59.1 59.5 0.74
Prior MI 19.5 19.4 0.9 18.2 19.3 0.25
Smoking 34.0 33.2 0.39 34.1 33.3 0.46
Dyslipidemia 76.8 73.4 <0.001 72.9 74.1 0.23
Prior revascularization 33.8 34.1 0.76 33.3 33.8 0.59
Chronic ASA use 19.8 19.5 0.68 19.9 19.6 0.75
Family history of CAD 8.1 7.6 0.39 7.6 7.6 1.00
Ventricular arrhythmia 4.7 5.0 0.54 5.1 4.8 0.56
Cardiogenic shock 3.3 2.1 <0.001 2.2 2.1 0.81
AKI 31.8 39.9 <0.001 39.3 38.6 0.52
Year
2010 14.2 13.5 0.34 13.5 13.3 0.84
2011 19.1 18.4 18.9 18.6
2012 20.6 21.3 20.7 21.5
2013 22.6 23.6 22.7 23.5
2014 23.5 23.2 24.2 23.1
Abbreviations: AKI, acute kidney injury; ASA, acetylsalicylic acid (aspirin); CAD, coronary artery disease; CVA, cerebrovascular accident; DM, diabetes mel-
litus; HTN, hypertension; IQR, interquartile range; MI, myocardial infarction; PCI, percutaneous coronary intervention; PSM, propensity score matching;
PVD, peripheral vascular disease.
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weekend admissions, AKI, chronic pulmonary disease, fluid and elec-
trolyte disorders, and DM were proportionally higher in the delayed
PCI group. The presence of dyslipidemia and cardiogenic shock was
higher in patients in the early PCI group. Otherwise, remaining vari-
ables, including year-to-year grouping, were not statistically signifi-
cant between the 2 groups (Table 3). After PSM, there was no
statistical difference between the 2 groups, and standardized mean
differences substantially reduced for all variables (<5%).
3.2 | Outcomes
Before PSM, there was no statistically significant difference between
the early and delayed PCI groups for in-hospital mortality (1.8% vs
1.5%; P = 0.19) or AKI-D (2.2% vs 2.3%; P = 0.83). The secondary
outcomes, median total hospital costs, and length of stay were higher
in the delayed PCI group ($77 616 vs $68 413, P < 0.001; and 4 vs
3 days, P < 0.001, respectively). After PSM, there was no statistically
significant difference for in-hospital mortality (1.9% vs 1.4%;
P = 0.12) or AKI-D (2.5% vs 2.3%; P = 0.54). The delayed PCI group
had higher median cost ($77 529 vs $70 554; P < 0.001) and longer
length of stay (4 vs 3 days; P < 0.001; Table 4).
4 | DISCUSSION
Among the cohort of patients with CKD and NSTE-ACS identified in
this large national database, early PCI was not associated with a sig-
nificant increase in the incidence of AKI-D or in-hospital mortality
compared with delayed PCI. Early PCI was associated with reduced
hospital costs and length of stay. Patients with CKD are more likely
to have significant comorbidities including DM, prior heart failure,
prior MI, peripheral arterial disease, and prior revascularization com-
pared with patients with normal renal function.13 Among patients
undergoing PCI, these comorbidities are associated with a high risk of
adverse events including severe bleeding, the need for dialysis, and
in-hospital mortality.13–15
Patients with CKD are a vital group to examine because CKD is
strongly associated with in-hospital mortality and bleeding in NSTEMI
patients undergoing PCI.13–15 A subgroup analysis of the Treat
Angina With Aggrastat and Determine the Cost of Therapy With
Invasive or Conservative Strategy–Thrombolysis In Myocardial Infarc-
tion (TACTICS-TIMI 18) study examined the interaction between cre-
atinine (Cr) clearance, outcomes, and the use of an early invasive
management strategy. The authors found that in patients with a mild
to moderate decrease in renal function, early invasive management
was superior to a conservative approach.16 The study was, however,
limited to patients with Cr <2.5 mg/dL, as the original trial excluded
patients with serum Cr >2.5 mg/dL. In the Timing of Intervention in
Acute Coronary Syndromes (TIMACS) trial, early intervention
improved the composite outcome of mortality, MI, and stroke at
6 months.5 However, renal function was not identified in this study.
We did not observe any mortality benefit based on timing of PCI.
Although the early PCI group had higher prevalence of cardiogenic
shock, there was no difference in the unadjusted mortality rate
between the 2 groups (3.3% vs 2.1%). After adjusting for cardiogenic
shock, the mortality difference between the 2 groups was not signifi-
cant. We believe that low incidence, and 1.1% absolute difference of
cardiogenic shock patients between both groups, would not have sig-
nificantly impacted the mortality. Moreover, comorbidity burden
between the 2 groups is statistically insignificant, except for DM, dys-
lipidemia, and AKI, suggesting that the patient population in the
2 groups is similar.
CKD is the greatest risk factor for CIN.17–20 AKI after angiogra-
phy is a significant risk factor for long-term mortality and end-stage
renal disease requiring dialysis.19 Utilizing the National Cardiovascular
Data Registry (NCDR) Cath-PCI registry, Tsai et al. reported that
CKD was associated with a 2-fold to 28-fold increased risk of AKI-
D.17 Their study reported a 0.07% incidence of AKI-D post-PCI in
patients with normal renal function, compared with 4.3% in patients
with severe CKD. Importantly, they observed that AKI-D after PCI
was associated with increased mortality.17 We observed a lower
TABLE 4 Outcomes of patients before and after PSM
Before PSM
Variables Early Stenting, n = 7705 Delayed Stenting, n = 3946 OR (95% CI) P Value
Died 1.8 1.5 0.81 (0.60-1.11) 0.19
Dialysis, % 2.2 2.3 1.03 (0.80-1.33) 0.83
Total charge in USD (IQR) 68 413 (48 400–98 889)a 77 616 (55 914–111 156)b — <0.001
LOS, d (IQR) 3 (2–4)a 4 (3–6)b — <0.001
After PSM
Variables Early Stenting, n = 3708 Delayed Stenting, n = 3708 OR (95% CI) P Value
Died 1.9 1.4 0.75 (0.53-1.08) 0.12
Dialysis, % 2.5 2.3 0.91 (0.68-1.23) 0.54
Total charge in USD (IQR) 70 554 (50 187–101 885)c 77 529 (55 820–110 470)d — <0.001
LOS, d (IQR) 3 (2–5)c 4 (3–6)d — <0.001
Abbreviations: CI, confidence interval; IQR, interquartile range; LOS, length of stay; OR, odds ratio; PSM, propensity score matching; USD, US dollars.
a n = 7568.
b n = 3890.
c n = 3638.
d n = 3655.
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incidence of AKI-D because our cohort consisted of all stages of
CKD. The American College of Cardiology (ACC)/American Heart
Association (AHA)/Society for Cardiovascular Angiography and Inter-
ventions (SCAI) guidelines recommend hydration for 3 to 12 hours
prior to undergoing angiography with contrast media.14 Hydration
and minimizing the dose of contrast administered are proven to
reduce the risk of CIN.21 A prospective study showed a very low
(2.4%) incidence of CIN in patients who received guideline-
recommended hydration prior to contrast administration. None of
their 747 patients required dialysis. On the contrary, a recently pub-
lished randomized trial showed that the rates of CIN were identical
between patients who received intravenous (IV) hydration vs those
who did not.22 They also found that IV hydration added to hospital
cost and length of stay. A single-center retrospective cohort study of
patients undergoing PCI found that participants with a high ratio of
hydration volume to weight actually had higher rates of CIN-AKI and
worse outcomes overall.23 Their findings challenge the established
concept that IV hydration prevents CIN and suggest that it may even
cause harm. However, these studies did not disclose whether they
analyzed patients with CKD. Many experts still insist that IV hydra-
tion remains the standard of care in patients with CKD.24 Though we
could not determine if patients in the delayed PCI group received
adequate hydration, the delay did not reduce the incidence of post-
PCI AKI-D.
There are no randomized controlled trials evaluating the value of
an early vs a delayed invasive strategy in patients with NSTEMI and
CKD. The Optimised Procedure in Patients with NSTEMI and CKD
(NSTEMI-CKD) trial was attempted (NCT02543177), but it was ter-
minated early due to poor enrollment.25 Our retrospective analysis of
a large population of patients with NSTEMI and CKD suggests car-
diac catheterization and PCI should not be delayed because of renal
dysfunction. A prospective randomized trial will be required to test
this hypothesis.
4.1 | Study limitations
There are important limitations to this study. The study was based on
a database that may have errors in the assignment of appropriate
diagnosis and procedure codes. Although we used PSM to correct for
confounding factors, the result may have been influenced by the non-
randomized assignment and inability to correct for confounding fac-
tors that were not included in the algorithm. We could not determine
the clinical reasons influencing the timing of PCI. The delayed PCI
group included patients with a significantly higher proportion of
comorbidities including DM, fluid and electrolyte disorders, AKI, and
weekend admission. The Cr level or glomerular filtration rate at the
time of PCI is a critical piece of information that is not provided in
the database. Furthermore, a large proportion of patients had “unspe-
cified” CKD (ICD-9-CM code 585.9); therefore, a subgroup analysis
of CKD stages was not practical. These factors could have influenced
the timing of cardiac catheterization. One of the determinants of
AKI-D is the volume of contrast. We could not control this variable
because the information was not available in the database. All these
limitations may have been minimized by PSM. After PSM, the net dif-
ference between the groups was significantly reduced, measured by
standardized mean difference, mitigating the influence of the comor-
bidities on the timing of PCI.
5 | CONCLUSION
Among patients with CKD and NSTE-ACS, the incidence of AKI-D
and in-hospital mortality was not significantly affected by the timing
of PCI. However, delayed PCI added significant hospital cost and
length of stay. These findings suggest early PCI in patients with
NSTEMI and CKD may be a preferred strategy. A prospective ran-
domized study will be required to validate this concept.
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